{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T17:41:05Z","timestamp":1793814065776,"version":"4.6.1"},"reference-count":33,"publisher":"The Journal of Rheumatology","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Rheumatol"],"published-print":{"date-parts":[[2016,9]]},"abstract":"<jats:sec><jats:title>Objective.<\/jats:title><jats:p>Serum C-reactive protein (CRP) associates with radiographic progression in patients with ankylosing spondylitis (AS) untreated with tumor necrosis factor (TNF) antagonists. We assessed correlations between serum CRP and radiographic progression\/magnetic resonance imaging (MRI)-detected inflammation after 2 years of anti-TNF therapy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods.<\/jats:title><jats:p>Patients with active AS receiving golimumab (GOL)\/placebo through Week 16 (early escape) or Week 24 (crossover by design), followed by GOL through 4 years, had sera\/images obtained through Week 208. Lateral spinal radiographs and spinal MRI were scored with the modified Stoke AS Spine Score (mSASSS) and the AS spine MRI activity (ASspiMRI-a) score, respectively. ANOVA assessed differences based on CRP levels and mSASSS progression. The relationships between CRP levels and mSASSS\/ASspiMRI-a were assessed by Spearman correlation and logistic regression.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results.<\/jats:title><jats:p>Of the randomized GO-RAISE patients, 299 (84.0%) had pre- and posttreatment spinal radiographs. Larger proportions of patients with Week 104 CRP \u2265 0.5 mg\/dl (n = 47) versus &lt; 0.5 mg\/dl (n = 236, 40.4% vs 22.9%, p = 0.0121) had mSASSS changes \u2265 2 at Week 104. Across several visits, serum CRP demonstrated weak associations with mSASSS change (r<jats:sub>s<\/jats:sub>\u2264 0.21, p &lt; 0.05, n = 262\u2013293) and moderate associations with ASspiMRI-a change (r<jats:sub>s<\/jats:sub>= \u22120.33 to 0.54, p &lt; 0.05, n = 65\u201389). Higher baseline CRP was associated with increased risk for syndesmophytes at Week 104\/Week 208, and large, short-term decreases in CRP from baseline to Week 14\/Week 24 also yielded increased syndesmophyte formation risk.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion.<\/jats:title><jats:p>Elevated CRP after 2 years of anti-TNF treatment correlated with greater radiographic progression risk at 4 years. Elevated CRP at baseline or Week 14\/Week 24 of anti-TNF treatment weakly predicted subsequent radiographic progression and modestly predicted residual spinal inflammation in patients with AS treated with anti-TNF. Findings are useful regarding new treatment options in patients treated with anti-TNF.<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"ClinicalTrials.gov\" ext-link-type=\"uri\" xlink:type=\"simple\">ClinicalTrials.gov<\/jats:ext-link>:<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT00265083\">NCT00265083<\/jats:ext-link>.<\/jats:p><\/jats:sec>","DOI":"10.3899\/jrheum.160003","type":"journal-article","created":{"date-parts":[[2016,7,16]],"date-time":"2016-07-16T01:59:01Z","timestamp":1468634341000},"page":"1704-1712","source":"Crossref","is-referenced-by-count":45,"title":["Serum C-reactive Protein Levels Demonstrate Predictive Value for Radiographic and Magnetic Resonance Imaging Outcomes in Patients with Active Ankylosing Spondylitis Treated with Golimumab"],"prefix":"10.3899","volume":"43","author":[{"given":"J\u00fcrgen","family":"Braun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xenofon","family":"Baraliakos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kay-Geert A.","family":"Hermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2262","published-online":{"date-parts":[[2016,7,15]]},"reference":[{"key":"2018112909361032000_43.9.1704.1","doi-asserted-by":"publisher","DOI":"10.1007\/s11926-012-0282-2"},{"key":"2018112909361032000_43.9.1704.2","doi-asserted-by":"publisher","DOI":"10.1002\/art.10883"},{"key":"2018112909361032000_43.9.1704.3","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2011-200308"},{"key":"2018112909361032000_43.9.1704.4","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-203425"},{"key":"2018112909361032000_43.9.1704.5","doi-asserted-by":"publisher","DOI":"10.1002\/art.23471"},{"key":"2018112909361032000_43.9.1704.6","doi-asserted-by":"publisher","DOI":"10.1002\/art.23901"},{"key":"2018112909361032000_43.9.1704.7","doi-asserted-by":"publisher","DOI":"10.1186\/ar2794"},{"key":"2018112909361032000_43.9.1704.8","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kem166"},{"key":"2018112909361032000_43.9.1704.9","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-203075"},{"key":"2018112909361032000_43.9.1704.10","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1002\/art.38070","article-title":"The impact of tumor necrosis factor \u03b1 inhibitors on radiographic progression in ankylosing spondylitis","volume":"65","author":"Haroon","year":"2013","journal-title":"Arthritis Rheum"},{"key":"2018112909361032000_43.9.1704.11","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.145995"},{"key":"2018112909361032000_43.9.1704.12","doi-asserted-by":"publisher","DOI":"10.1002\/art.33465"},{"key":"2018112909361032000_43.9.1704.13","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.071605"},{"key":"2018112909361032000_43.9.1704.14","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.138883"},{"key":"2018112909361032000_43.9.1704.15","doi-asserted-by":"publisher","DOI":"10.1002\/art.30627"},{"key":"2018112909361032000_43.9.1704.16","doi-asserted-by":"publisher","DOI":"10.1002\/art.23969"},{"key":"2018112909361032000_43.9.1704.17","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2011.154799"},{"key":"2018112909361032000_43.9.1704.18","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780270401"},{"key":"2018112909361032000_43.9.1704.19","first-page":"2286","article-title":"A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index","volume":"21","author":"Garrett","year":"1994","journal-title":"J Rheumatol"},{"key":"2018112909361032000_43.9.1704.20","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-205862"},{"key":"2018112909361032000_43.9.1704.21","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.020503"},{"key":"2018112909361032000_43.9.1704.22","doi-asserted-by":"publisher","DOI":"10.1002\/art.24483"},{"key":"2018112909361032000_43.9.1704.23","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keu263"},{"key":"2018112909361032000_43.9.1704.24","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-205178"},{"issue":"Suppl 2","key":"2018112909361032000_43.9.1704.25","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1136\/annrheumdis-2015-eular.1792","article-title":"Factors associated with structural damage in the spine, as measured by x-ray, in patients with axial spondyloarthritis treated with certolizumab pegol over 96 weeks","volume":"74","author":"van der Heijde","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"2018112909361032000_43.9.1704.26","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-203419"},{"key":"2018112909361032000_43.9.1704.27","doi-asserted-by":"publisher","DOI":"10.1186\/ar2496"},{"key":"2018112909361032000_43.9.1704.28","doi-asserted-by":"publisher","DOI":"10.1002\/art.30393"},{"key":"2018112909361032000_43.9.1704.29","doi-asserted-by":"publisher","DOI":"10.1002\/art.24132"},{"key":"2018112909361032000_43.9.1704.30","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.110767"},{"key":"2018112909361032000_43.9.1704.31","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2011-200208"},{"key":"2018112909361032000_43.9.1704.32","doi-asserted-by":"publisher","DOI":"10.1186\/ar2035"},{"key":"2018112909361032000_43.9.1704.33","doi-asserted-by":"publisher","DOI":"10.1016\/S0167-5699(00)01625-X"}],"container-title":["The Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3899\/jrheum.160003","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,18]],"date-time":"2024-06-18T07:46:39Z","timestamp":1718696799000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jrheum.org\/lookup\/doi\/10.3899\/jrheum.160003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7,15]]},"references-count":33,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2016,9,1]]},"published-print":{"date-parts":[[2016,9]]}},"alternative-id":["10.3899\/jrheum.160003"],"URL":"https:\/\/doi.org\/10.3899\/jrheum.160003","relation":{},"ISSN":["0315-162X","1499-2752"],"issn-type":[{"value":"0315-162X","type":"print"},{"value":"1499-2752","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,7,15]]}}}